Title
Organophosphate pesticide exposure and attention in young Mexican-American children: the CHAMACOS study.

Permalink
https://escholarship.org/uc/item/4fq0x5bk

Journal
Environmental health perspectives, 118(12)

ISSN
0091-6765

Authors
Marks, Amy R
Harley, Kim
Bradman, Asa
et al.

Publication Date
2010-12-01

DOI
10.1289/ehp.1002056

Peer reviewed
Organophosphate Pesticide Exposure and Attention in Young Mexican-American Children: The CHAMACOS Study

Amy R. Marks,1 Kim Harley,1 Asa Bradman,1 Katherine Kogut,1 Dana Boyd Barr,2 Caroline Johnson,1 Norma Calderon,3 and Brenda Eskenazi1

1Center for Children’s Environmental Health Research, School of Public Health, University of California, Berkeley, Berkeley, California, USA; 2Emory University, Rollins School of Public Health, Atlanta, Georgia, USA; 3Center for the Health Assessment of Mothers and Children of Salinas, Clinica de Salud del Valle de Salinas, Salinas, California, USA

BACKGROUND: Exposure to organophosphate (OP) pesticides, well-known neurotoxins, has been associated with neurobehavioral deficits in children.

OBJECTIVES: We investigated whether OP exposure, as measured by urinary dialkyl phosphate (DAP) metabolites in pregnant women and their children, was associated with attention-related outcomes among Mexican-American children living in an agricultural region of California.

METHODS: Children were assessed at ages 3.5 years (n = 331) and 5 years (n = 323). Mothers completed the Child Behavior Checklist (CBCL). We administered the NEPSY-II visual attention subtest to children at 3.5 years and Conners’ Kiddie Continuous Performance Test (K-CPT) at 5 years. The K-CPT yielded a standardized attention deficit/hyperactivity disorder (ADHD) Confidence Index score. Psychometricians scored behavior of the 5-year-olds during testing using the Hillside Behavior Rating Scale.

RESULTS: Prenatal DAPs (nanomoles per liter) were nonsignificantly associated with maternal report of attention problems and ADHD at age 3.5 years but were significantly related at age 5 years [CBCL attention problems: β = 0.7 points; 95% confidence interval (CI), 0.2–1.2; ADHD: β = 1.3; 95% CI, 0.4–2.1]. Prenatal DAPs were associated with scores on the K-CPT ADHD Confidence Index > 70th percentile [odds ratio (OR) = 5.1; 95% CI, 1.7–15.7] and with a composite ADHD indicator of the various measures (OR = 3.5; 95% CI, 1.1–10.7). Some outcomes exhibited evidence of effect modification by sex, with associations found only among boys. There was also limited evidence of associations between child DAPs and attention.

CONCLUSIONS: In utero DAPs and, to a lesser extent, postnatal DAPs were associated adversely with attention as assessed by maternal report, psychometrician observation, and direct assessment. These associations were somewhat stronger at 5 years than at 3.5 years and were stronger in boys.

KEY WORDS: ADHD, attention, Child Behavior Checklist, DAPs, farmworker, Mexican Americans, neurobehavior, organophosphates, pesticides. Environ Health Perspect 118:1768–1774 (2010). doi:10.1289/ehp.1002056 (Online 19 August 2010)

Organophosphate (OP) pesticides are potent toxicants that target the nervous systems of insects and other pests (Jokanovic 2009). OPs operate primarily through the inhibition of acetylcholinesterase, an enzyme that degrades the neurotransmitter acetylcholine, resulting in a buildup of acetylcholine in the neuronal junction (Jeyaratnam and Maroni 1994). However, cholinergic inhibition may not be the sole mechanism of effect, particularly in cases of low-level exposure (Costa 2006; Ray and Richards 2001; Timofeeva et al. 2008). Although accounts of human poisoning with these compounds have reported symptoms such as impaired concentration, slowed information processing and motor function, anxiety, confusion, tremors, seizure, and death (Jeyaratnam and Maroni 1994; Levin and Rodnitzky 1976), few studies have investigated the health effects in humans of low-level chronic exposure to OP pesticides. The potential effects of such low-level exposures on neurobehavioral functioning are particularly relevant for fetuses and young children, who may be especially vulnerable to neurotoxics because of their immature nervous systems, their rapid rate of brain growth and development in utero and during early childhood, and their low levels of the enzymes involved in the metabolism and detoxification of OP pesticides (Eskenazi et al. 1999; Huen et al. 2009). Animal studies have found adverse effects of OP exposure during the prenatal and early postnatal periods (Costa 2006; Eskenazi et al. 1999).

Although research is limited, a few recent epidemiologic studies have reported associations between in utero OP exposure and adverse effects on neurobehavioral development (Engel et al. 2007; Eskenazi et al. 2007; Rauh et al. 2006; Young et al. 2005). These studies have found that biomarkers of prenatal OP exposure are associated with an increased number of abnormal neonatal reflexes, as measured by the Brazelton Scales of Neonatal Development (Engel et al. 2007; Young et al. 2005), and poorer mental development in early childhood, as measured on the Bayley Scales of Infant Development (Eskenazi et al. 2007; Rauh et al. 2006). Rauh et al. (2006) also found in a cohort of 3-year-olds living in New York City that concentrations of the OP pesticide chlorpyrifos in maternal serum were associated with the mothers’ report of symptoms consistent with pervasive developmental disorder (PDD) as well as of attention deficit/hyperactivity disorder (ADHD) or attention problems. A recent cross-sectional study also reported associations between child OP metabolite concentrations and ADHD in 8- to 15-year-olds representative of the U.S. population (Bouchard et al. 2010). Although we previously reported that prenatal OP metabolite concentrations were associated with mothers’ report of PDD symptoms in 2-year-olds living in the agricultural Salinas Valley of California, we did not find an association between maternal or child dialkyl phosphates (DAPs) and measures of attention at 2 years of age (Eskenazi et al. 2007). However, the children in our study were younger—potentially too young at 2 years of age to manifest attention problems or for mothers to detect them. Although ADHD, characterized by inattention, impulsivity, and/or hyperactivity, is occasionally diagnosed in children as young as 2 or 3 years, it is more apparent after children begin school and is more commonly reported in boys than...
in girls (Pastor and Reuben 2008; Staller and Faraone 2006).

The aim of this paper is to investigate associations between in utero and childhood OP pesticide exposure as assessed by urinary DAP metabolites and attention-related outcomes in 3.5- and 5-year-old Mexican-American children living in an agricultural community in California. We include assessment of attentional problems based not only on maternal report, as in previous studies, but also by direct neuropsychological testing and psychometrician observation.

**Materials and Methods**

**Participants and recruitment.** The Center for the Health Assessment of Mothers and Children of Salinas (CHAMACOS) is a prospective birth cohort aimed at studying the association of pesticides and other environmental agents on the health of pregnant women and their children living in the Salinas Valley, California. Details for this study have been described previously (Eskenazi et al. 2004, 2007). Briefly, women in their first half of pregnancy were recruited between October 1999 and October 2000 from participating prenatal care clinics serving the farmworker community. Eligible women were ≥ 18 years of age, eligible for California’s low-income health insurance program, planning to deliver at the county medical center, and spoke Spanish or English. Women gave written informed consent to participate. The study was approved by the institutional review board at University of California, Berkeley.

We followed 526 women to delivery of a liveborn, surviving singleton. We excluded from the present analyses children who did not have a prenatal DAP metabolite measurement \( n = 2 \), who had a medical condition that could affect neurobehavioral assessment \( n = 3 \); deafness, Down syndrome, hydrocephalus, or who were lost to follow-up or did not participate at the 3.5- or 5-year study visit \( n = 173 \). The final population included 348 children who had available data at 3.5 and/or 5 years of age. Total DAPs were measured in maternal urine collected at two time points during pregnancy and in child urine collected at the 3.5-year and 5-year visits. Levels of DAPs were similar in mothers of children included in the present analysis relative to those whose children were not \( t \)-test \( p = 0.40 \). Distributions of other covariates measured before 3.5 years of age were also similar, except that more boys than girls had dropped from the study \( \chi^2 = 0.04 \).

**Maternal interviews and assessments.** We interviewed mothers twice during pregnancy (mean gestation, 14.0 and 26.6 weeks), after delivery, and when children were 6 months and 1, 2, 3.5, and 5 years of age. Interviews were conducted by bilingual, bicultural interviewers in Spanish or English. Mothers were administered the Peabody Picture Vocabulary Test (PPVT) (Dunn and Dunn 1981; Dunn et al. 1986) at the 6-month visit to assess receptive vocabulary, which was used as an indicator of verbal intelligence, and the Center for Epidemiologic Studies Depression Scale (CES-D) (Radloff 1977) at the 3.5-year visit. A registered nurse abstracted prenatal and delivery medical records.

**Attention-related outcomes.** We measured attention-related outcomes in three ways: maternal report of child behavior at 3.5 and 5 years of age; direct assessment of the child at 3.5 and 5 years; and psychometrician’s report of the behavior of the child during testing at 5 years.

Mothers completed the Child Behavior Checklist (CBCL) for 1.5–5 years of age (Achenbach and Rescorla 2000) as part of the maternal interview at the 3.5- and 5-year visits to assess emotional/behavioral problems and competencies of the children. This 99-item scale, which is available in English and Spanish and has been widely used in cross-cultural research, collects data on a variety of behaviors that the parent rates as “not true,” “somewhat true,” or “very true/often true” currently or within the preceding 2 months. Questions are combined to create scores reflecting possible problem areas, including some corresponding to Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) diagnoses (American Psychiatric Association 2000) and others reflecting problem syndrome areas. The present analyses focused on two related attention scores: the attention problems scale and the DSM-related ADHD scale. Scores can be examined continuously or by the proportion above a standard cutoff score, for example, > 93rd percentile (borderline clinical range) or > 97th percentile (clinical range). Because few children fell into the clinical-range category for these scales \( n = 3–11 \), we used the borderline clinical range cut-point as well as continuous raw scores in multivariate analyses.

Children also completed a battery of neurodevelopmental tests at each visit. At the 3.5-year visit, the visual attention subtest of the NEPSY-II (Korkman et al. 1997) was administered to children by trained psychometricians. Children were asked to circle specific images on a page of pictures that included distracters. For data analysis, we used continuous scores scaled to a normative sample of U.S. children; the age-standardized mean ± SD for this subscale is 10 ± 3.

During the 5-year neurodevelopmental assessment, which took approximately 2 hr to complete, trained psychometricians administered to children the Conners’ Kiddie Continuous Performance Test (K-CPT) (Conners and Staff 2001). The K-CPT is a 7-min computerized test that assesses reaction time, accuracy, and impulse control. Briefly, children were instructed to press the space bar when they saw any image on the computer screen except a ball. The computer program yields T-scores age-standardized to a general U.S. population (mean ± SD = 50 ± 10) for errors of commission (i.e., the child responds when he or she should not), errors of omission (i.e., the child fails to respond when he or she should), and hit reaction time. We examined T-scores continuously and categorically using the cutoff of T-score > 65, which is considered markedly atypical. The program also combines measures to generate a clinical ADHD Confidence Index score (range, 0–100). For statistical analyses, we use continuous Confidence Index percentiles and selected a cut-point of > 70th percentile (meaning that 70% of children performing similarly on the test could be correctly classified as having clinical ADHD).

Following the 5-year neurodevelopmental assessment, psychometricians blinded to exposure status answered several subjective questions evaluating the behavior of the child during the 2-hr visit, including four questions derived from the seven-item Hillside Behavior Rating Scale (Gittelman and Klein 1985). We summed responses to two questions assessing motor activity and distractibility to create an adapted ADHD symptoms scale. The Hillside Scale is associated with parent and teacher ratings and has been found to add significantly to the clinical prediction of ADHD (Willcutt et al. 1999). We created a dichotomized Hillside outcome variable with scores ≥ 7 of 12 possible points (representing < 10% of children) to flag children displaying a higher degree of attention problems based on psychometricians’ observation.

To identify children whose behaviors on multiple indices at 5 years of age were most suggestive of possible ADHD within our cohort, we created a composite ADHD variable that combined maternal report (CBCL), child testing (K-CPT), and psychometrician report (Hillside). Children were coded 1 for the ADHD indicator if they met at least two of the following conditions at 5 years of age: CBCL ADHD scale in borderline clinical range (maternal report); standardized K-CPT ADHD Confidence Index ≥ 60% (child testing); and Hillside ADHD scale in the upper quartile of values (psychometrician report).

The CBCL was completed by 331 mothers at the 3.5-year interview and 323 mothers at the 5-year interview. NEPSY scores were available for 320 3.5-year-olds, and K-CPT scores were available for 312 5-year-olds. Hillside scores were available for 322 5-year-olds.

**Pesticide exposure measurement.** Details of urine collection, analysis, and quality control procedures, including detection limits and use of blanks and spikes, are described elsewhere.
We measured six DAP metabolites in maternal and child urine: \( O, O \)-dimethyl phosphate (DM) metabolites (dimethylphosphate, dimethylthiophosphate, dimethyldithiophosphate), representing breakdown of \( O, O \)-dimethyl-substituted OP pesticides such as malathion, oxymethon-methyl, and dime thoate, and \( b \) three diethyl phosphate (DE) metabolites (diethylphosphate, diethylthiophosphate, and diethyl dithiophosphate) derived from \( O, O \)-diethyl-substituted OP pesticides such as chlorpyrifos and diazinon (Bradman et al. 2005). These six metabolites cannot be traced back to individual pesticides but, taken together, represent the breakdown products of approximately 80% of the total OP pesticides used in the Salinas Valley. Values below the limit of detection (LOD) were assigned a value of LOD/\( 2 \). Urinary creatinine concentrations were determined using a commercially available diagnostic enzyme method (Vitros CREA slides; Ortho Clinical Diagnostics, Raritan, NJ).

Lead, which we considered a potential confounder, was measured in cord blood by the California State Department of Public Health (Sacramento, CA) and in children’s blood at age 2 years by the Monterey County Public Health Laboratory (Salinas, CA) using graphite furnace atomic absorption spectrophotometry. Lead levels were abstracted from laboratory and clinic medical records by the study staff.

**Data analysis.** We performed analyses using Stata version 10.1 (StataCorp, College Station, TX). DAPs (nanomoles per liter) were summed and transformed to the log (base 10) scale; coefficients and odds ratios (ORs) thus represent the change in mean behavioral scores or relative odds of an outcome for each 10-fold increase in DAP concentration.

Pregnancy DM, DE, and total DAP values were created by averaging the two log-transformed pregnancy measures. For 19 women with only one DAP measurement in pregnancy, the single measure was used. Several children were missing DAP measures at 3.5 years (\( n = 58 \)) and 5 years (\( n = 14 \)). Separate models were run with maternal DAPs only, child DAPs only, and the two together in the same model.

We conducted a number of sensitivity analyses. We re-ran all models using creatinine-adjusted DAP metabolite concentrations. In addition, we added to final models some factors potentially on the causal pathway (i.e., birth weight, gestational duration). We also considered whether controlling for lead (log10-transformed), a known neurotoxicant, altered results for DAP concentrations in the subsamples with cord (\( n = 229 \)) or 2-year (\( n = 296 \)) lead values. Finally, because rates of ADHD vary considerably by sex in the general population (Pastor and Reuben 2008) and effects of other toxicants have been found to vary by sex (Delaney-Black et al. 2004), we tested for interactions between DAP concentrations and child sex, using \( p < 0.15 \) for the interaction term to determine whether associations of DAP concentrations with measures of attention differed for boys and girls.

**Results**

**Demographic characteristics.** Demographic characteristics of the study population are presented in Table 1. Mean (± SD) maternal age at delivery was 26.5 ± 5.2 years at delivery. Most mothers were married or living as married (82%), spoke only Spanish at home (90%), were born in Mexico (86%), had not completed high school (79%), were nonsmokers (96%), and lived in a low-income household (97%) within 200% of the federal threshold for poverty;
63% within 100%). One third of mothers were primiparous, and almost half of mothers had symptoms of depression (CES-D ≥ 16). About half of the children were in regular out-of-home child care at 3.5 years of age, and by 5 years, 69% had attended some preschool. At the time of their 5-year assessment, almost one third of children had started kindergarten.

**Urinary DAP concentrations.** OP metabolite concentrations are summarized in Table 2. The geometric mean (GM) of average prenatal maternal urinary DAP concentrations was 109.0 nmol/L. The two pregnancy DAP measurements were weakly correlated ($r = 0.15$; $p = 0.009$). The DAP concentrations were lower in children than in mothers during pregnancy. Child DAPs were uncorrelated with maternal DAPs (Pearson $r = 0.03$; $p = 0.60$ with 3.5-year measures and $r = -0.02$; $p = 0.77$ with 5-year measures).

**Attention in children 3.5 and 5 years of age.** When children were 3.5 years old, approximately 5% of mothers reported child behaviors that were in the borderline clinical range for attention problems and ADHD symptoms, with poorer scores on CBCL attention-related scales among boys than among girls (see Supplemental Material, Table 1 [doi:10.1289/ehp.1002056]). The NEPSY visual attention scores averaged 8.8 ± 2.3.

When children were 5 years old, 4% of their mothers reported behaviors consistent with attention problems and 7% reported ADHD symptoms in the borderline clinical range; again, scores were higher in boys than in girls [see Supplemental Material, Table 1 (doi:10.1289/ehp.1002056)]. On the K-CPT, 19% of children scored markedly atypical for errors of omission, 17% for errors of commission, and 6% for hit reaction time; taken together, 8% of children scored ≥ 70% on the standardized ADHD Confidence Index scale. Boys had higher average scores on the ADHD Confidence Index than girls [see Supplemental Material, Table 1 (doi:10.1289/ehp.1002056)]. Psychometricians rated 7% of children ≥ 7 on ADHD-related behaviors on the Hillside scale, and 8.5% of children were classified as having ADHD symptoms at 5 years according to the composite score.

Continuous CBCL scores were correlated across ages (Pearson $r = 0.46–0.54$; $p < 0.01$), and at each age, all continuous attention measures were correlated with one another (Pearson $r = 0.16–0.85$; $p < 0.01$) except for the NEPSY test of visual attention, which was not correlated with any outcome ($r = -0.09$ to 0.04).

**Relation between prenatal DAPs and attention.** Table 3 (categorical outcomes) and Table 4 (continuous outcomes) present the relationship of prenatal DAP concentrations and measures of child attention, not controlling for child DAPs in the models. Adding child DAPs as a covariate produced very similar results (data not shown).

When the children were 3.5 years of age, prenatal DAP concentrations were positively associated with attention problems [OR = 3.0; 95% confidence interval (CI), 0.7–11.7; $p = 0.12$] and ADHD (OR = 3.1; 95% CI, 0.8–11.5; $p = 0.09$) in the borderline clinical range on the CBCL, although estimates were not statistically significant.

When the children were 5 years of age, prenatal total DAP levels, and DM levels specifically, were associated with maternal report (CBCL) of both ADHD scores and poorer attention scores when the scores were examined as continuous outcomes (Table 4) but not as categorical outcomes (Table 3). Total DAP concentrations (and total DM and DE concentrations separately) were nonsignificantly associated with the continuous K-CPT ADHD Confidence Index scores (Table 4) and were significantly associated with this index when it was modeled as a dichotomous variable (Table 3). Specifically, for each 10-fold increase in DAP concentrations, children had five times the odds of scoring > 70% on the ADHD Confidence Index (OR = 5.1; 95% CI, 1.7–15.7). Prenatal total DAP concentrations were nonsignificantly associated with the psychometrician Hillside ratings of poor attention (OR = 3.0; 95% CI, 0.9–8.8; $p = 0.06$). Total DAP concentrations, and DM concentrations were nonsignificantly associated with the标准化 ADHD Confidence Index (OR = 3.0; 95% CI, 0.9–8.8; $p = 0.06$).

### Table 2. GM concentrations (nmol/L) of average maternal urinary DAP metabolites during pregnancy, CHAMACOS Study, Salinas Valley, California [GM (95% CI)]

| Marker of exposure* | Pregnancy (n = 340) | 3.5 Years (n = 290) | 5 Years (n = 320) |
|---------------------|---------------------|---------------------|-------------------|
| Total DAPs          | 109.0 (99.4–119.6)  | 77.5 (65.4–91.9)    | 92.6 (78.6–109.0) |
| Total DEs           | 17.7 (16.1–19.4)    | 7.0 (5.8–8.3)       | 7.2 (6.0–8.7)     |
| Total DMs           | 76.8 (69.3–85.0)    | 62.5 (52.2–74.7)    | 72.4 (61.0–86.0)  |

*Not adjusted for creatinine; measurements below the LOD were assigned a value of LOD/√2.

### Table 3. Adjusted* logistic models for attention-related outcomes at 3.5 and 5 years of age per 10-fold increase in prenatal urinary DAP concentrations [OR (95% CI)]

| Model               | n/Outcome D | DAPs | DEs | DMs |
|---------------------|-------------|------|-----|-----|
| 3.5 Years CBCL      | 330         | 0.3 (0.2–0.7)  | 0.3 (0.1–0.7)  |
| ADHD                | 329         | 0.5 (0.3–1.3)  | 0.6 (0.1–1.3)  |
| ADHD Indicator      | 27/319      | 3.5 (1.1–10.7) | 3.0 (1.1–8.2) |

*Adjusted for psychometrician, age at assessment, sex, child care, breastfeeding, maternal education, depressive symptoms, and PPVT. *p < 0.10. **p < 0.05. ***p < 0.01.

### Table 4. Adjusted* linear models for attention-related outcomes at 3.5 and 5 years of age per 10-fold increase in prenatal urinary DAP concentrations [β (95% CI)]

| Model               | n/Outcome D | DAPs | DMs | DEs |
|---------------------|-------------|------|-----|-----|
| 3.5 Years CBCL      | 330         | 0.7 (0.2 to 1.2) | 0.6 (0.2 to 1.0) |
| ADHD                | 329         | 1.3 (0.4 to 2.1) | 1.1 (0.3 to 1.9) |

*Adjusted for psychometrician, age at assessment, sex, child care, breastfeeding, maternal education, depressive symptoms, and PPVT. *p < 0.10. **p < 0.05.
specifically, were associated with having ADHD signs using the composite indicator (total DAPs OR = 3.5; 95% CI, 1.1–10.7), which is based on the three assessment methods (i.e., ADHD signs based on at least two of the three following measures: maternal report on the CBCL; child performance on the K-CPT; and psychometrician ratings on the Hillside scale) and is thus not independent of the individual components.

Using creatinine-adjusted DAP levels led to conclusions similar to those presented above [Supplemental Material, Tables 2 and 3 (doi:10.1289/ehp.1002056)]. Some relationships were stronger, whereas others were attenuated. In addition, birth weight, gestational age, breast-feeding, and lead did not confound associations between DAPs and attention or ADHD, because these factors did not independently affect the associations of prenatal DAP metabolite concentrations and maternal report of attention problems and ADHD symptoms on the CBCL; at 3.5 years and 5 years, no associations were seen for girls, but among boys, DAP concentrations were significantly associated with poorer attention and ADHD scores (Table 6). We also observed stronger associations among boys than among girls for several categorical outcomes, including CBCL outcomes in the borderline clinical range, high K-CPT Confidence Index scores, scoring ≥ 7 on the Hillside ADHD scale, and the composite measure, but only the interaction terms for the Hillside ADHD scale and composite ADHD indicator models were statistically significant (p < 0.15) (Table 5).

**Relation between child DAPs and attention.** We did not observe statistically significant associations between children’s concurrent total DAP concentrations and any of the measures of attention, whether we adjusted for creatinine or not (Tables 7 and 8) and with or without (not shown) maternal DAPs in the models. However, we did observe that for every 10-fold increase in child urinary DE concentration at 5 years, there was a doubling in the odds in the ADHD composite indicator variable (OR = 2.0; 95% CI, 1.1–3.6). We observed no statistically significant increase in adverse outcomes with child DM concentrations.

**Table 5.** Adjusted logistic models for attention-related outcomes at 3.5 and 5 years of age per 10-fold increase in prenatal urinary DAP concentrations, stratified by sex.

| Model | Boys | OR (95% CI) | OR (95% CI) | p-Value for interaction |
|-------|------|-------------|-------------|-------------------------|
| 3.5 Years | | | | |
| CBCL | Attention problems | 12/151 | 4.1 (0.9–22.2) | 5/179 | 2.1 (0.2–29.9) | 0.68 |
| ADHD | 12/151 | 6.4 (1.1–39.0)** | 6/176 | 1.0 (0.1–11.2) | 0.21 |
| 5 Years | | | | |
| CBCL | Attention problems | 10/154 | 1.0 (0.7–33.0) | 3/168 | 0.6 (0.0–17.3) | 0.77 |
| ADHD | 14/154 | 4.9 (0.7–33.0) | 13/164 | 1.7 (0.4–7.4) | 0.72 |
| K-CPT | Markedly atypical | 21/148 | 1.7 (0.4–6.4) | 38/164 | 1.4 (0.5–4.0) | 0.90 |
| Percent commissions | 24/148 | 0.9 (0.2–3.2) | 30/164 | 1.2 (0.4–3.3) | 0.99 |
| Hit reaction time | 7/147 | 1.2 (0.1–11.5) | 13/164 | 1.7 (0.4–7.4) | 0.72 |
| ADHD Confidence Index | > 70th percentile | 14/140 | 10.1 (1.6–65.3)** | 11/157 | 3.3 (0.6–17.0) | 0.41 |
| Hillside Behavioral Rating Scale | Attention ≥ 7 of 12 | 14/153 | 7.9 (1.4–46.0)** | 9/169 | 1.0 (0.2–5.9) | 0.14 |
| Composite ADHD indicator | 19/150 | 11.1 (1.8–66.5)** | 8/169 | 1.1 (0.2–7.1) | 0.13 |

*Adjusted for psychometrician, age at assessment, sex, maternal education, depressive symptoms, PPVT, child care, and breast-feeding. **p < 0.05. *p < 0.01.

**Table 6.** Adjusted linear models for continuous attention-related outcomes at 3.5 and 5 years of age per 10-fold increase in prenatal urinary DAP concentrations, stratified by sex.

| Model | Boys | n | β (95% CI) | Girls | n | β (95% CI) | p-Value for interaction |
|-------|------|---|-------------|-------|---|-------------|-------------------------|
| 3.5 Years | CBCL | Attention problems | 151 | 0.7 (0.0–1.4)** | 179 | −0.1 (−0.7 to 0.5) | 0.05 |
| ADHD | 151 | 1.3 (0.1–2.5)** | 179 | −0.2 (−1.2 to 0.8) | 0.06 |
| NEPSY | Visual attention | 143 | 0.2 (0.8–1.1) | 176 | 0.2 (−0.7 to 1.2) | 0.99 |
| 5 Years | CBCL | Attention problems | 154 | 0.9 (0.2–1.7)** | 168 | 0.4 (0.2–1.0) | 0.28 |
| ADHD | 154 | 1.9 (0.5–3.2)** | 168 | 0.6 (0.0–1.6) | 0.13 |
| K-CPT | ADHD Confidence Index | 140 | 6.3 (0.5–13.3)* | 157 | 0.5 (−7.2 to 8.3) | 0.39 |

*Adjusted for psychometrician, age at assessment, sex, maternal education, depressive symptoms, PPVT, child care, and breast-feeding. **p < 0.10. *p < 0.05. /p < 0.01.
child urinary DAPs and attention-related performance errors on the Wisconsin Card Sorting Test; however the population was small (n = 48) (Lizardi et al. 2008). In the present study, associations between attention measures and prenatal DAPs are stronger than those with child DAP concentrations. Furthermore, results with child DAPs must be viewed with caution, because they reflect concurrent exposures, the temporal relation with the outcome is unclear, and exposure may not be independent of childhood behavior.

We find some evidence of effect modification by sex of the child. The clinical presentation of attention deficit disorder may vary by the child’s sex, with girls reportedly displaying more inattentive-type problems and boys displaying more hyperactive and impulsive behaviors (Biederman et al. 2002; Staller and Faraone 2006). Studies of other substances have found marked differences in neurotoxic susceptibility by sex. For example, one study found that 6-year-old boys prenatally exposed to cocaine displayed more problem behaviors (hyperactivity) than controls but observed no such differences among girls (Delaney-Black et al. 2004). A recent meta-analysis reported that differences in brain morphology between youth with ADHD and controls varied by child sex (Hutchinson et al. 2008), and a functional imaging study found that men with ADHD displayed different neural activity patterns than controls, but women did not (Valera et al. 2010).

The mechanisms by which OPs could cause attentional problems and/or impulsivity can be only speculated, as ADHD is a complex disorder and the precise causes are unknown. However, there is considerable evidence that neurotransmitters including dopamine, noradrenaline, and serotonin, the primary target of ADHD pharmacologic treatments, are involved. Less is known about the role of the cholinergic system. Although OP pesticides at high doses will inhibit acetylcholinesterase, experimental evidence in animals suggests that even OP doses that cause no or little cholinesterase inhibition may produce biochemical and behavioral effects (Costa 2006), including adverse effects on sustained attention and an increase in impulsivity in rodents (Middlemore-Risher et al. 2010). In addition, there is a growing body of evidence that OPs may operate through a variety of noncholinergic mechanisms, such as by disruption of various cellular processes such as DNA replication and axonal and dendritic growth (Howard et al. 2005) and by oxidative stress in the developing brain (Slotkin and Seidler 2009).

Our study has many strengths. We were able to assess prenatal OP exposure and follow the children longitudinally. Our findings are generally consistent whether we use creatinine or non-creatinine-adjusted DAP metabolite concentrations. Although DAP concentrations were not associated with all outcomes, we found evidence for an association across various assessment methods, including maternal report, child testing, and subjective observation by evaluators blinded to exposure.

This study has some limitations. Notably, the assessment of exposure to OPs is challenging because of the rapid metabolism of OP pesticides (Needham 2005) and the lack of a measure of long-term exposure; however, because the prenatal measures are an average of two measurements, they may better reflect ongoing exposure during the pregnancy. Also, the prenatal maternal urinary DAP concentrations in our study are higher than in a homogeneous study population.

Another limitation is that some of the measures we used to assess behavior in these Mexican-American children were standardized for the general U.S. population. Therefore, the percentage of children identified as having a problem may not be comparable with that expected for the general U.S. population. Nevertheless, this limitation should not affect the examination of the relative associations of DAPs and outcomes within our own homogeneous study population.

Future studies should evaluate whether associations of OP exposure and attention disorders persist in older children and in children in different populations. ADHD is often not diagnosed until children are of school age, and screening instruments may identify attention problems more accurately in older children than in preschoolers. In addition, future investigations should consider whether children with certain genetic polymorphisms (e.g., paraoxonase 1) may be more likely to show attention problems in relation to OP exposure. Approximately 8–9% of school-age children are estimated to have ADHD (Pastor and Reuben 2008); given that attention

Table 7. Adjusted* logistic regression model for attention-related outcomes at ages 3.5 and 5 years per 10-fold increase in child urinary DAP concentrations [OR (95% CI)].

| Model | OR (95% CI) | p Value |
|-------|-------------|---------|
| 3.5 Years | | |
| CBCL | | |
| Attention problems | 1.6 (0.8–3.5) | 0.9 (0.8–3.9) |
| ADHD | 1.4 (0.7–3.1) | 1.0 (0.5–2.2) |
| 5 Years | | |
| CBCL | | |
| Attention problems | 1.0 (0.4–2.4) | 1.8 (0.3–3.9) |
| ADHD | 0.6 (0.3–1.2) | 0.9 (0.5–1.7) |

*Adjusted for maternal total DAPs, psychometrician, age at assessment, sex, maternal education, depressive symptoms, PPVT, child care, and breast-feeding, as well as maternal urinary DAPs. **p < 0.05.

Table 8. Adjusted* linear regression models for attention-related outcomes at ages 3.5 and 5 years per 10-fold increase in child urinary DAP concentrations [β (95% CI)].

| Model | n | Total DAPs | DMs | DEs |
|-------|---|------------|-----|-----|
| 3.5 Years | | |
| CBCL | | |
| Attention problems | 0.1 (–0.2 to 0.4) | 0.1 (–0.2 to 0.3) | 0.2 (0.0 to 0.5)* |
| ADHD | 0.1 (–0.3 to 0.6) | 0.1 (–0.3 to 0.6) | 0.2 (–0.3 to 0.7) |
| NEPSY | | |
| Visual attention | | |
| 5 Years | | |
| CBCL | | |
| Attention problems | 0.0 (–0.3 to 0.2) | 0.0 (–0.3 to 0.2) | 0.0 (–0.2 to 0.3) |
| ADHD | 0.0 (–0.3 to 0.5) | 0.0 (–0.3 to 0.5) | 0.1 (–0.3 to 0.6) |

*Adjusted for maternal total DAPs, psychometrician, age at assessment, sex, maternal education, depressive symptoms, PPVT, child care, and breast-feeding, as well as maternal urinary DAPs. *p < 0.10.
problems of children interfere with learning and social development, finding potential causes that can be remediated are of great public health importance.

Conclusion

*In utero* DAP and, to a lesser extent, child DAP concentrations were associated adversely with attention in young children as assessed by maternal report, psychometrician observation, and/or direct assessment. These associations were somewhat stronger at 5 years than at 3.5 years and in boys than in girls.

**References**

Achenbach T, Rescorla L. 2000. Manual for the ASEBA Preschool Forms and Profiles. Burlington, VT:University of Vermont, Research Center for Children, Youth, and Families. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC:American Psychiatric Association. Biederman J, Mick E, Faraone SV, Braaten E, Doyle A, Spencer T, et al. 2002. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 159(1):36–42. Bouchard MF, Bellinger DC, Wright RD, Weisskopf MG. 2010. Attention-deficit/hyperactivity disorder and urinary metabolites of organophosphate pesticides. Pediatrics 125:e1270–e1277. Bradman A, Eskenazi B, Barr D, Castorina R. 2009. Organophosphate pesticide exposure and gender moderation. J Dev Behav Pediatr 30(4):342–351. Bradman A, Eskenazi B, Castorina R, Chevrier J, et al. 2005. Organophosphorous and carbamate pesticide exposure and abnormal developmental outcomes in children. Environ Health Perspect 113:1802–1807. Bravo R, Driskell WJ, Whitehead RD Jr, Needham LL, Barr DB. 2004. Association of in utero organophosphate pesticide exposure and gender on neuropsychological performance in children. Neurotoxicology 25(4):254–263. Dunn L, Dunn L. 1981. Peabody Picture Vocabulary Test, Revised. Circle Pines, MN:American Guidance Service. Dunn L, Padilla E, Lugo D, Dunn L. 1986. Test de Vocabulario en Imagenes Peabody: Adaptacion Hispanoamericana (Peabody Picture Vocabulary Test: Hispanic-American Adaptation). Circle Pines, MN:Dunn Educational Services, Inc. Engel SM, Berkowitz GS, Barr DB, Teitelbaum SL, Siskind J, Meisel SJ, et al. 2007. Prenatal organophosphate metabolite and organochlorine levels and performance on the Brazelton Neonatal Behavioral Assessment Scale in a multi-ethnic pregnancy cohort. Am J Epidemiol 165(12):1397–1404. Eskenazi B, Bradman A, Castorina R. 1999. Exposures of children to organophosphate pesticides and their potential adverse health effects. Environ Health Perspect 107(suppl 3):409–418. Eskenazi B, Harley C, Bradman A, Weltzien E, Jewell NP, Barr DB, et al. 2004. Association of in utero organophosphate pesticide exposure and fetal growth and length of gestation in an agricultural population. Environ Health Perspect 112(1):21–13. Gittelman RG, Klein D. 1985. Hillside Behavior Rating Scale. Psychopharmacol Bull 21:896–899. Howard AS, Bucelli R, Jett DA, Bruun D, Yang D, Lein PJ. 2005. Chlorpyrifos exerts opposing effects on axonal and dendritic growth in primary neuronal cultures. Toxicol Appl Pharmacol 207(2):112–124. Huen K, Harley C, Brooks J, Hubbard A, Bradman A, Eskenazi B, et al. 2009. Developmental changes in PON1 enzyme activity in young children and effects of PON1 polymorphisms. Environ Health Perspect 117:567–570. Johnson C, et al. 2007. Organophosphate pesticide exposure and neurodevelopment in the first 3 years of life among inner-city children. Pediatrics 118(6):e1845–e1859. Ray DE, Richards PG. 2001. The potential for toxic effects of chronic, low-dose exposure to organophosphates. Toxicol Lett 120(1–3):343–351. Slotkin TA, Stein E. 2009. Oxidative and excitatory mechanisms of developmental neurotoxicity: transcriptional profiles for chlorpyrifos, diazinon, diethyl, and dieldrin in PC12 cells. Environ Health Perspect 117:567–570. Staller J, Faraone SV. 2008. Attention-deficit hyperactivity disorder in girls: epidemiology and management. CNS Drugs 20(2):107–122. Timofeeva OA, Sanders D, Seemann K, Yang L, Hermanson D, Hegedus K, et al. 2009. Persistent behavioral alterations in rats neonatally exposed to low doses of the organophosphate pesticide, parathion. Brain Res Bull 77(6):404–411. U.S. Census Bureau. 2000. Poverty Thresholds 2000, Current Population Survey. Washington, DC:U.S. Census Bureau. Valera EM, Brower A, Biederman J, Faraone SV, Makris N, Monuteaux MC, et al. 2010. Sex differences in the functional neuroanatomy of working memory in adults with ADHD. Am J Psychiatry 167(1):186–94. Willcutt EG, Hartung CM, Lahey BB, Loney J, Pelham WE. 1999. Utility of behavior ratings by examiners during assessments of preschool children with attention-deficit/hyperactivity disorder. J Abnorm Child Psychol 27(6):463–472. Young JG, Eskenazi B, Gladstone EA, Bradman A, Pederson L, Johnson C, et al. 2005. Association between in utero organophosphate pesticide exposure and abnormally high rates of premature birth. Environ Health Perspect 113:1802–1807.